Assistant Professor Maureen McKeague obtained her PhD at Carleton University in 2012. She moved to the Department of Bioengineering at Stanford University from 2012-2016 for an NSERC postdoctoral fellowship, then transitioned to ETH Zurich for 2 years as a senior researcher in the Department of Health Sciences and Technology. She joined the Department of Pharmacology and Therapeutics in 2018 and is jointly appointed in the Department of Chemistry.
The McKeague lab is interested in defining the basis of chemotherapy resistance/sensitivity and to exploit these findings for patient stratification and the development of novel therapeutics. The lab employs a genomic chemistry approach that combines: (1) sequencing DNA damage distribution in the cancer genome; (2) characterizing DNA damage dynamics with real-time fluorescence monitoring; and (3) identifying novel DNA-based repair inhibitors.